KPS-0373, High dose + KPS-0373, Low dose
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Spinocerebellar Degeneration
Conditions
Spinocerebellar Degeneration
Trial Timeline
— → —
NCT ID
NCT01970124About KPS-0373, High dose + KPS-0373, Low dose
KPS-0373, High dose + KPS-0373, Low dose is a phase 3 stage product being developed by Kissei Pharmaceutical for Spinocerebellar Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT01970124. Target conditions include Spinocerebellar Degeneration.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01970124 | Phase 3 | Completed |
| NCT01970111 | Phase 3 | Completed |
| NCT01970137 | Phase 3 | Completed |
Competing Products
15 competing products in Spinocerebellar Degeneration
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KPS-0373, High dose + KPS-0373, Low dose + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 2 | 51 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 | Kissei Pharmaceutical | Phase 2 | 51 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| varenicline + placebo | Pfizer | Phase 2 | 51 |
| BIIB132 + BIIB132-Matching Placebo | Biogen | Phase 1 | 30 |
| IVIG | Baxter | Phase 2 | 49 |
| Intravenous Immune Globulin (IVIG) | Baxter | Phase 1 | 30 |
| ARO-ATXN2 Injection + Placebo | Arrowhead Pharmaceuticals | Phase 1 | 30 |
| Troriluzole + Placebo + Troriluzole | Biohaven | Phase 2/3 | 60 |
| BHV-4157 | Biohaven | Pre-clinical | 18 |
| troriluzole + Placebo | Biohaven | Phase 3 | 72 |